Novo Nordisk Upgraded to Buy with Catalysts in Sight

24 days ago

Chloe Melle

"Novo Nordisk was upgraded to a buy rating by HSBC, moving from a hold. Analysts highlighted that the company might gradually turn a corner by focusing on its reimbursed medical and direct-to-consumer channels, although its next generation portfolio remains suboptimal compared to Eli Lilly. Potential catalysts include the Evoque trial for Alzheimer\'s."

The segment provides a clear trade call for Novo Nordisk, following an upgrade from hold to buy by HSBC. The rationale centers on channel improvements and potential catalysts like the Evoque trial for Alzheimer\'s, despite some concerns over its next-generation portfolio relative to competitors.

Related Stocks